In a twist that feels straight out of Silicon Valley déjà vu, Billy Evans—the husband of Theranos founder Elizabeth Holmes—is main a brand new well being tech startup known as Haemanthus.
The corporate, nonetheless working in stealth mode, is elevating each capital and issues, drawing rapid comparisons to the now-infamous Theranos scandal.
Regardless of being underneath the radar, Haemanthus has reportedly raised over $18 million from buyers, with plans to safe extra. The startup guarantees a “radically new strategy” to well being diagnostics by combining Raman spectroscopy—a light-based molecular detection approach—with synthetic intelligence. The thought is to investigate tiny samples of blood, sweat, or urine for early indicators of illness.
Echoes of Theranos—With a Twist?
Haemanthus markets itself as “the way forward for diagnostics,” a tagline that’s onerous to disregard given the Theranos fallout. Including to the comparisons, early prototypes of the corporate’s gadget are mentioned to resemble Theranos’ defunct Edison machine. However the group is raring to attract a line within the sand.
“This isn’t Theranos 2.0,” Haemanthus just lately posted on social platform X. The corporate says it’s not attempting to shrink down current lab assessments right into a field, as Theranos did, however is as an alternative constructing a essentially totally different diagnostic system from the bottom up.
The identify “Haemanthus”—a flower also called the blood lily—is a symbolic nod to the corporate’s mission. Nonetheless, the startup’s low profile, lack of public contact data, and closed-door communication type have raised pink flags amongst business watchers.
The Holmes Connection
Although Holmes is at present serving an 11-year sentence in a Texas jail for defrauding buyers, she’s reportedly nonetheless concerned behind the scenes, informally advising Evans as he builds the corporate. Whereas she’s banned from main any public firm for a decade, there’s no legislation stopping her from contributing to a non-public one.
That involvement is sufficient to make many within the biotech world uneasy. Tyler Shultz, a former Theranos worker and whistleblower, just lately wrote, “She appears to be attempting once more,” in a cautionary op-ed.
Innovation or Phantasm?
Haemanthus says it’s targeted on “human well being optimization” and even plans to check its tech on pets earlier than shifting to human diagnostics. Using Raman spectroscopy and AI is scientifically professional and intriguing, however consultants are urging warning.
“There’s a cause individuals are skeptical,” mentioned Dr. Geoffrey Baird, chair of laboratory drugs on the College of Washington. “I want there have been a solution to quick a inventory earlier than an organization even exists.”
Why it’s intriguing:
- Innovation potential: Haemanthus leverages Raman spectroscopy and AI, that are professional and promising diagnostic applied sciences.
- New strategy: Not like Theranos, which miniaturized current assessments, Haemanthus claims to be constructing a essentially totally different system.
Why it’s regarding:
- Theranos’ legacy: The connection to Holmes, who’s at present serving time for fraud, casts an extended shadow. Public belief is fragile.
- Secrecy: The corporate’s stealth mode and lack of transparency echo early Theranos techniques, elevating pink flags.
- Investor danger: With $18 million already raised, there’s concern about whether or not due diligence is being correctly performed.
This could possibly be a real try at innovation—or a repeat of historical past. The important thing distinction will lie in transparency, scientific validation, and regulatory oversight.
Public Reactions: A Mixture of Curiosity and Cynicism
On social media, reactions have ranged from astonishment to outright mockery: “Have we realized nothing?”.
Memes evaluating Haemanthus to Theranos have gone viral, with many questioning how a venture with such a detailed connection to Holmes might appeal to severe funding once more.
Nonetheless, buyers seem intrigued—maybe too intrigued. With $18 million already within the financial institution, critics are asking whether or not sufficient due diligence is being carried out to keep away from a repeat of previous errors.
Haemanthus, for its half, appears conscious of the uphill battle it faces. In a latest publish, the corporate acknowledged: “Sure, our CEO, Billy Evans, is Elizabeth Holmes’ accomplice. Skepticism is rational. We should clear the next bar.”
They insist Holmes has “zero involvement” and that their strategy is “essentially totally different” from Theranos.
*The Rise and Fall of Theranos
Theranos was based in 2003 by Elizabeth Holmes, who dropped out of Stanford College at age 19 with the formidable objective of revolutionizing healthcare by making blood testing sooner, cheaper, and fewer invasive. The corporate claimed it might carry out lots of of diagnostic assessments utilizing just some drops of blood from a finger prick, utilizing its proprietary gadget referred to as the Edison.
Backed by influential buyers and board members—together with former Secretaries of State Henry Kissinger and George Shultz—Theranos reached a peak valuation of $9 billion, and Holmes was extensively hailed as a visionary, even drawing comparisons to Steve Jobs for her black turtlenecks and branding type.
However in 2015, a collection of investigative stories by John Carreyrou of The Wall Avenue Journal revealed that Theranos’ know-how didn’t work as claimed. In actuality, most of the assessments had been being carried out utilizing commercially accessible machines, not the Edison gadget, and sometimes yielded inaccurate or unreliable outcomes.
The exposé triggered investigations by federal regulators, together with the Facilities for Medicare & Medicaid Providers (CMS), the SEC, and the Division of Justice. In 2016, Theranos was banned from working a blood-testing lab, and the corporate rapidly started to unravel.
In 2018, Holmes and former Theranos president and COO Ramesh “Sunny” Balwani had been charged with a number of counts of wire fraud and conspiracy to commit wire fraud. That very same yr, Theranos was formally dissolved.
In January 2022, after a prolonged trial, Holmes was discovered responsible on 4 counts of fraud and conspiracy associated to defrauding buyers. She was sentenced to 11 years and three months in federal jail and started serving her sentence in Might 2023 at a minimum-security facility in Texas.
In a twist that feels straight out of Silicon Valley déjà vu, Billy Evans—the husband of Theranos founder Elizabeth Holmes—is main a brand new well being tech startup known as Haemanthus.
The corporate, nonetheless working in stealth mode, is elevating each capital and issues, drawing rapid comparisons to the now-infamous Theranos scandal.
Regardless of being underneath the radar, Haemanthus has reportedly raised over $18 million from buyers, with plans to safe extra. The startup guarantees a “radically new strategy” to well being diagnostics by combining Raman spectroscopy—a light-based molecular detection approach—with synthetic intelligence. The thought is to investigate tiny samples of blood, sweat, or urine for early indicators of illness.
Echoes of Theranos—With a Twist?
Haemanthus markets itself as “the way forward for diagnostics,” a tagline that’s onerous to disregard given the Theranos fallout. Including to the comparisons, early prototypes of the corporate’s gadget are mentioned to resemble Theranos’ defunct Edison machine. However the group is raring to attract a line within the sand.
“This isn’t Theranos 2.0,” Haemanthus just lately posted on social platform X. The corporate says it’s not attempting to shrink down current lab assessments right into a field, as Theranos did, however is as an alternative constructing a essentially totally different diagnostic system from the bottom up.
The identify “Haemanthus”—a flower also called the blood lily—is a symbolic nod to the corporate’s mission. Nonetheless, the startup’s low profile, lack of public contact data, and closed-door communication type have raised pink flags amongst business watchers.
The Holmes Connection
Although Holmes is at present serving an 11-year sentence in a Texas jail for defrauding buyers, she’s reportedly nonetheless concerned behind the scenes, informally advising Evans as he builds the corporate. Whereas she’s banned from main any public firm for a decade, there’s no legislation stopping her from contributing to a non-public one.
That involvement is sufficient to make many within the biotech world uneasy. Tyler Shultz, a former Theranos worker and whistleblower, just lately wrote, “She appears to be attempting once more,” in a cautionary op-ed.
Innovation or Phantasm?
Haemanthus says it’s targeted on “human well being optimization” and even plans to check its tech on pets earlier than shifting to human diagnostics. Using Raman spectroscopy and AI is scientifically professional and intriguing, however consultants are urging warning.
“There’s a cause individuals are skeptical,” mentioned Dr. Geoffrey Baird, chair of laboratory drugs on the College of Washington. “I want there have been a solution to quick a inventory earlier than an organization even exists.”
Why it’s intriguing:
- Innovation potential: Haemanthus leverages Raman spectroscopy and AI, that are professional and promising diagnostic applied sciences.
- New strategy: Not like Theranos, which miniaturized current assessments, Haemanthus claims to be constructing a essentially totally different system.
Why it’s regarding:
- Theranos’ legacy: The connection to Holmes, who’s at present serving time for fraud, casts an extended shadow. Public belief is fragile.
- Secrecy: The corporate’s stealth mode and lack of transparency echo early Theranos techniques, elevating pink flags.
- Investor danger: With $18 million already raised, there’s concern about whether or not due diligence is being correctly performed.
This could possibly be a real try at innovation—or a repeat of historical past. The important thing distinction will lie in transparency, scientific validation, and regulatory oversight.
Public Reactions: A Mixture of Curiosity and Cynicism
On social media, reactions have ranged from astonishment to outright mockery: “Have we realized nothing?”.
Memes evaluating Haemanthus to Theranos have gone viral, with many questioning how a venture with such a detailed connection to Holmes might appeal to severe funding once more.
Nonetheless, buyers seem intrigued—maybe too intrigued. With $18 million already within the financial institution, critics are asking whether or not sufficient due diligence is being carried out to keep away from a repeat of previous errors.
Haemanthus, for its half, appears conscious of the uphill battle it faces. In a latest publish, the corporate acknowledged: “Sure, our CEO, Billy Evans, is Elizabeth Holmes’ accomplice. Skepticism is rational. We should clear the next bar.”
They insist Holmes has “zero involvement” and that their strategy is “essentially totally different” from Theranos.
*The Rise and Fall of Theranos
Theranos was based in 2003 by Elizabeth Holmes, who dropped out of Stanford College at age 19 with the formidable objective of revolutionizing healthcare by making blood testing sooner, cheaper, and fewer invasive. The corporate claimed it might carry out lots of of diagnostic assessments utilizing just some drops of blood from a finger prick, utilizing its proprietary gadget referred to as the Edison.
Backed by influential buyers and board members—together with former Secretaries of State Henry Kissinger and George Shultz—Theranos reached a peak valuation of $9 billion, and Holmes was extensively hailed as a visionary, even drawing comparisons to Steve Jobs for her black turtlenecks and branding type.
However in 2015, a collection of investigative stories by John Carreyrou of The Wall Avenue Journal revealed that Theranos’ know-how didn’t work as claimed. In actuality, most of the assessments had been being carried out utilizing commercially accessible machines, not the Edison gadget, and sometimes yielded inaccurate or unreliable outcomes.
The exposé triggered investigations by federal regulators, together with the Facilities for Medicare & Medicaid Providers (CMS), the SEC, and the Division of Justice. In 2016, Theranos was banned from working a blood-testing lab, and the corporate rapidly started to unravel.
In 2018, Holmes and former Theranos president and COO Ramesh “Sunny” Balwani had been charged with a number of counts of wire fraud and conspiracy to commit wire fraud. That very same yr, Theranos was formally dissolved.
In January 2022, after a prolonged trial, Holmes was discovered responsible on 4 counts of fraud and conspiracy associated to defrauding buyers. She was sentenced to 11 years and three months in federal jail and started serving her sentence in Might 2023 at a minimum-security facility in Texas.
In a twist that feels straight out of Silicon Valley déjà vu, Billy Evans—the husband of Theranos founder Elizabeth Holmes—is main a brand new well being tech startup known as Haemanthus.
The corporate, nonetheless working in stealth mode, is elevating each capital and issues, drawing rapid comparisons to the now-infamous Theranos scandal.
Regardless of being underneath the radar, Haemanthus has reportedly raised over $18 million from buyers, with plans to safe extra. The startup guarantees a “radically new strategy” to well being diagnostics by combining Raman spectroscopy—a light-based molecular detection approach—with synthetic intelligence. The thought is to investigate tiny samples of blood, sweat, or urine for early indicators of illness.
Echoes of Theranos—With a Twist?
Haemanthus markets itself as “the way forward for diagnostics,” a tagline that’s onerous to disregard given the Theranos fallout. Including to the comparisons, early prototypes of the corporate’s gadget are mentioned to resemble Theranos’ defunct Edison machine. However the group is raring to attract a line within the sand.
“This isn’t Theranos 2.0,” Haemanthus just lately posted on social platform X. The corporate says it’s not attempting to shrink down current lab assessments right into a field, as Theranos did, however is as an alternative constructing a essentially totally different diagnostic system from the bottom up.
The identify “Haemanthus”—a flower also called the blood lily—is a symbolic nod to the corporate’s mission. Nonetheless, the startup’s low profile, lack of public contact data, and closed-door communication type have raised pink flags amongst business watchers.
The Holmes Connection
Although Holmes is at present serving an 11-year sentence in a Texas jail for defrauding buyers, she’s reportedly nonetheless concerned behind the scenes, informally advising Evans as he builds the corporate. Whereas she’s banned from main any public firm for a decade, there’s no legislation stopping her from contributing to a non-public one.
That involvement is sufficient to make many within the biotech world uneasy. Tyler Shultz, a former Theranos worker and whistleblower, just lately wrote, “She appears to be attempting once more,” in a cautionary op-ed.
Innovation or Phantasm?
Haemanthus says it’s targeted on “human well being optimization” and even plans to check its tech on pets earlier than shifting to human diagnostics. Using Raman spectroscopy and AI is scientifically professional and intriguing, however consultants are urging warning.
“There’s a cause individuals are skeptical,” mentioned Dr. Geoffrey Baird, chair of laboratory drugs on the College of Washington. “I want there have been a solution to quick a inventory earlier than an organization even exists.”
Why it’s intriguing:
- Innovation potential: Haemanthus leverages Raman spectroscopy and AI, that are professional and promising diagnostic applied sciences.
- New strategy: Not like Theranos, which miniaturized current assessments, Haemanthus claims to be constructing a essentially totally different system.
Why it’s regarding:
- Theranos’ legacy: The connection to Holmes, who’s at present serving time for fraud, casts an extended shadow. Public belief is fragile.
- Secrecy: The corporate’s stealth mode and lack of transparency echo early Theranos techniques, elevating pink flags.
- Investor danger: With $18 million already raised, there’s concern about whether or not due diligence is being correctly performed.
This could possibly be a real try at innovation—or a repeat of historical past. The important thing distinction will lie in transparency, scientific validation, and regulatory oversight.
Public Reactions: A Mixture of Curiosity and Cynicism
On social media, reactions have ranged from astonishment to outright mockery: “Have we realized nothing?”.
Memes evaluating Haemanthus to Theranos have gone viral, with many questioning how a venture with such a detailed connection to Holmes might appeal to severe funding once more.
Nonetheless, buyers seem intrigued—maybe too intrigued. With $18 million already within the financial institution, critics are asking whether or not sufficient due diligence is being carried out to keep away from a repeat of previous errors.
Haemanthus, for its half, appears conscious of the uphill battle it faces. In a latest publish, the corporate acknowledged: “Sure, our CEO, Billy Evans, is Elizabeth Holmes’ accomplice. Skepticism is rational. We should clear the next bar.”
They insist Holmes has “zero involvement” and that their strategy is “essentially totally different” from Theranos.
*The Rise and Fall of Theranos
Theranos was based in 2003 by Elizabeth Holmes, who dropped out of Stanford College at age 19 with the formidable objective of revolutionizing healthcare by making blood testing sooner, cheaper, and fewer invasive. The corporate claimed it might carry out lots of of diagnostic assessments utilizing just some drops of blood from a finger prick, utilizing its proprietary gadget referred to as the Edison.
Backed by influential buyers and board members—together with former Secretaries of State Henry Kissinger and George Shultz—Theranos reached a peak valuation of $9 billion, and Holmes was extensively hailed as a visionary, even drawing comparisons to Steve Jobs for her black turtlenecks and branding type.
However in 2015, a collection of investigative stories by John Carreyrou of The Wall Avenue Journal revealed that Theranos’ know-how didn’t work as claimed. In actuality, most of the assessments had been being carried out utilizing commercially accessible machines, not the Edison gadget, and sometimes yielded inaccurate or unreliable outcomes.
The exposé triggered investigations by federal regulators, together with the Facilities for Medicare & Medicaid Providers (CMS), the SEC, and the Division of Justice. In 2016, Theranos was banned from working a blood-testing lab, and the corporate rapidly started to unravel.
In 2018, Holmes and former Theranos president and COO Ramesh “Sunny” Balwani had been charged with a number of counts of wire fraud and conspiracy to commit wire fraud. That very same yr, Theranos was formally dissolved.
In January 2022, after a prolonged trial, Holmes was discovered responsible on 4 counts of fraud and conspiracy associated to defrauding buyers. She was sentenced to 11 years and three months in federal jail and started serving her sentence in Might 2023 at a minimum-security facility in Texas.
In a twist that feels straight out of Silicon Valley déjà vu, Billy Evans—the husband of Theranos founder Elizabeth Holmes—is main a brand new well being tech startup known as Haemanthus.
The corporate, nonetheless working in stealth mode, is elevating each capital and issues, drawing rapid comparisons to the now-infamous Theranos scandal.
Regardless of being underneath the radar, Haemanthus has reportedly raised over $18 million from buyers, with plans to safe extra. The startup guarantees a “radically new strategy” to well being diagnostics by combining Raman spectroscopy—a light-based molecular detection approach—with synthetic intelligence. The thought is to investigate tiny samples of blood, sweat, or urine for early indicators of illness.
Echoes of Theranos—With a Twist?
Haemanthus markets itself as “the way forward for diagnostics,” a tagline that’s onerous to disregard given the Theranos fallout. Including to the comparisons, early prototypes of the corporate’s gadget are mentioned to resemble Theranos’ defunct Edison machine. However the group is raring to attract a line within the sand.
“This isn’t Theranos 2.0,” Haemanthus just lately posted on social platform X. The corporate says it’s not attempting to shrink down current lab assessments right into a field, as Theranos did, however is as an alternative constructing a essentially totally different diagnostic system from the bottom up.
The identify “Haemanthus”—a flower also called the blood lily—is a symbolic nod to the corporate’s mission. Nonetheless, the startup’s low profile, lack of public contact data, and closed-door communication type have raised pink flags amongst business watchers.
The Holmes Connection
Although Holmes is at present serving an 11-year sentence in a Texas jail for defrauding buyers, she’s reportedly nonetheless concerned behind the scenes, informally advising Evans as he builds the corporate. Whereas she’s banned from main any public firm for a decade, there’s no legislation stopping her from contributing to a non-public one.
That involvement is sufficient to make many within the biotech world uneasy. Tyler Shultz, a former Theranos worker and whistleblower, just lately wrote, “She appears to be attempting once more,” in a cautionary op-ed.
Innovation or Phantasm?
Haemanthus says it’s targeted on “human well being optimization” and even plans to check its tech on pets earlier than shifting to human diagnostics. Using Raman spectroscopy and AI is scientifically professional and intriguing, however consultants are urging warning.
“There’s a cause individuals are skeptical,” mentioned Dr. Geoffrey Baird, chair of laboratory drugs on the College of Washington. “I want there have been a solution to quick a inventory earlier than an organization even exists.”
Why it’s intriguing:
- Innovation potential: Haemanthus leverages Raman spectroscopy and AI, that are professional and promising diagnostic applied sciences.
- New strategy: Not like Theranos, which miniaturized current assessments, Haemanthus claims to be constructing a essentially totally different system.
Why it’s regarding:
- Theranos’ legacy: The connection to Holmes, who’s at present serving time for fraud, casts an extended shadow. Public belief is fragile.
- Secrecy: The corporate’s stealth mode and lack of transparency echo early Theranos techniques, elevating pink flags.
- Investor danger: With $18 million already raised, there’s concern about whether or not due diligence is being correctly performed.
This could possibly be a real try at innovation—or a repeat of historical past. The important thing distinction will lie in transparency, scientific validation, and regulatory oversight.
Public Reactions: A Mixture of Curiosity and Cynicism
On social media, reactions have ranged from astonishment to outright mockery: “Have we realized nothing?”.
Memes evaluating Haemanthus to Theranos have gone viral, with many questioning how a venture with such a detailed connection to Holmes might appeal to severe funding once more.
Nonetheless, buyers seem intrigued—maybe too intrigued. With $18 million already within the financial institution, critics are asking whether or not sufficient due diligence is being carried out to keep away from a repeat of previous errors.
Haemanthus, for its half, appears conscious of the uphill battle it faces. In a latest publish, the corporate acknowledged: “Sure, our CEO, Billy Evans, is Elizabeth Holmes’ accomplice. Skepticism is rational. We should clear the next bar.”
They insist Holmes has “zero involvement” and that their strategy is “essentially totally different” from Theranos.
*The Rise and Fall of Theranos
Theranos was based in 2003 by Elizabeth Holmes, who dropped out of Stanford College at age 19 with the formidable objective of revolutionizing healthcare by making blood testing sooner, cheaper, and fewer invasive. The corporate claimed it might carry out lots of of diagnostic assessments utilizing just some drops of blood from a finger prick, utilizing its proprietary gadget referred to as the Edison.
Backed by influential buyers and board members—together with former Secretaries of State Henry Kissinger and George Shultz—Theranos reached a peak valuation of $9 billion, and Holmes was extensively hailed as a visionary, even drawing comparisons to Steve Jobs for her black turtlenecks and branding type.
However in 2015, a collection of investigative stories by John Carreyrou of The Wall Avenue Journal revealed that Theranos’ know-how didn’t work as claimed. In actuality, most of the assessments had been being carried out utilizing commercially accessible machines, not the Edison gadget, and sometimes yielded inaccurate or unreliable outcomes.
The exposé triggered investigations by federal regulators, together with the Facilities for Medicare & Medicaid Providers (CMS), the SEC, and the Division of Justice. In 2016, Theranos was banned from working a blood-testing lab, and the corporate rapidly started to unravel.
In 2018, Holmes and former Theranos president and COO Ramesh “Sunny” Balwani had been charged with a number of counts of wire fraud and conspiracy to commit wire fraud. That very same yr, Theranos was formally dissolved.
In January 2022, after a prolonged trial, Holmes was discovered responsible on 4 counts of fraud and conspiracy associated to defrauding buyers. She was sentenced to 11 years and three months in federal jail and started serving her sentence in Might 2023 at a minimum-security facility in Texas.
